Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$12 Mln
P/E Ratio
--
P/B Ratio
0.59
Industry P/E
--
Debt to Equity
--
ROE
-0.66 %
ROCE
-0 %
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-143.80 Mln
EBITDA
$-360.00 Mln
Net Profit
$-363.96 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
| -63.02 | -6.88 | -56.77 | -73.86 | -34.23 | -43.46 | -25.86 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Marker Therapeutics (MRKR)
| -43.19 | 106.84 | -71.58 | -34.48 | -49.65 | -48.11 | 41.31 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.19 | 10,226.85 | 20.76 | 23.13 | |
| 296.28 | 9,219.66 | 24.15 | 58.42 | |
| 24.72 | 10,361.50 | -- | -28.77 | |
| 101.38 | 9,388.25 | 28.84 | 14.16 |
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor... associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Address: 9350 Kirby Drive, Houston, TX, United States, 77054 Read more
Co-Founder, CEO, President, Treasurer & Director
Dr. Juan F. Vera M.D.
Co-Founder, CEO, President, Treasurer & Director
Dr. Juan F. Vera M.D.
Headquarters
Houston, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Marker Therapeutics Inc (MRKR) stood at $ 22,022,860 Mln as on 31-Dec-24
The share price of Marker Therapeutics Inc (MRKR) is $1.15 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Marker Therapeutics Inc (MRKR) has given a return of -34.23% in the last 3 years.
Marker Therapeutics Inc (MRKR) has a market capitalisation of $ 12 Mln as on 15-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Marker Therapeutics Inc (MRKR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Marker Therapeutics Inc (MRKR) and enter the required number of quantities and click on buy to purchase the shares of Marker Therapeutics Inc (MRKR).
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Address: 9350 Kirby Drive, Houston, TX, United States, 77054
The CEO & director of Dr. Juan F. Vera M.D.. is Marker Therapeutics Inc (MRKR), and CFO & Sr. VP is Dr. Juan F. Vera M.D..
There is no promoter pledging in Marker Therapeutics Inc (MRKR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,031
|
|
|
989
|
|
|
950
|
|
|
915
|
| Marker Therapeutics Inc. (MRKR) | Ratios |
|---|---|
|
Return on equity(%)
|
-0
|
|
Operating margin(%)
|
-0
|
|
Net Margin(%)
|
-0
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Marker Therapeutics Inc (MRKR) was $0 Mln.
$0.07
(
